Learn More
PURPOSE To evaluate the efficacy and safety of intravitreal bevacizumab as an adjunctive treatment to panretinal photocoagulation (PRP) for high-risk proliferative diabetic retinopathy with or without clinically significant macular edema (CSME). METHODS In forty-one eyes with high-risk proliferative diabetic retinopathy, intravitreal bevacizumab (1.25(More)
  • 1